In a regulatory filing, Cytokinetics disclosed that on April 23, the company entered into an employment offer letter with Sung Lee, pursuant to which Lee has agreed to serve as the company’s Executive Vice President, CFO, effective as of May 8. On the start date, Lee will assume the duties and responsibilities of the company’s principal financial officer from Robert Blum, the company’s President and CEO, who has been serving as the company’s principal financial officer on an interim basis
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics to Announce First Quarter Results on May 8, 2024
- Cytokinetics put volume heavy and directionally bearish
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
- Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
- Cytokinetics presents additional 48-week data from FOREST-HCM study